Department of Defense Inks $235.8 Million Contract for Anthrax Vaccines
Biopharmaceutical company Emergent BioSolutions (EBS) signed a massive $235.8 million contract with the Department of Defense to supply the U.S. military with its BioThrax anthrax vaccine.
Yahoo Finance reported the Biothrax anthrax vaccine is expected to be used by all branches of the U.S. military.
The Gateway Pundit previously reported that the FDA approved Emergent BioSolution’s Cyfendus anthrax vaccine for adults 18-65 in July of last year.
Just months later after its approval, Emergent BioSolutions announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) “exercised an option valued on an existing deal to procure additional doses of its recently approved anthrax vaccine Cyfendus (AV7909).”
#EmergentBiosolutionsInc #News #Contract #EBS #competitors Emergent BioSolutions Bags $235.8 Million Contract to Supply Anthrax Vaccine to U.S.
